Image courtesy of the Centers for Disease Control and Prevention (CDC) shows a transmission electron microscopic image of an isolate from the first US case of COVID-19.

Infectious Diseases globally are a continuing problem, as shown by the emergence of COVID-19 (SARS-CoV-2)

  • COVID-19 has reached pandemic status
  • Virtually every country on earth has seen COVID-19 infections
  • Death rates are estimated to be 2-3.4% of confirmed cases
  • As this is a novel virus, there is virtually no immunity in the global population
  • This combination of factors has led to unprecedented efforts to contain the virus and limit it’s spread

Our goal: Generate a safe and effective vaccine with animal data in 6 months or less.

HaloVax is a pre-clinical biotech company focused on bringing our Self-Assembling Vaccine (SAV) to patients at risk for COVID-19 infection.  We believe that our vaccine could be particularly effective and improve patient outcomes by engaging the immune system to identify and attack this pandemic infectious agent.

This technology has initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease.  This was done with the support of the DoD.  These same principles are being applied to developing a vaccine against the pandemic coronavirus, known as COVID-19

The SAV program has intellectual property surrounding composition of matter.  Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts which used classic adjuvants like alum, etc.  The vaccine is >90% HSP70 and Aviden.  Neoantigens are then incorporated to customize the vaccine.

We believe that the VaxCelerate technology has the potential to provide a differentiated approach to a COVID-19 vaccine.

HALOVAX at-a-glance

Background Halovax is a special purpose subsidiary of Voltron Therapeutics, Inc.
Technology
Licensed from the Vaccine & Immunotherapy Center (VIC) at the Massachusetts General Hospital, VaxCelerate has 2 elements: 1 fixed (immune adjuvant) and 1 variable (immune targeting).

VaxCelerate could offer several advantages over other vaccines in combination therapy:
  • In infectious applications, it allows rapid development against viruses and other pathogens

  • Generates customized cellular immunity

Target

COVID-19 (SARS-CoV-2)

Timeline